By Pushkala Aripaka and Bhanvi Satija Jan 20 (Reuters) - Britain's GSK has agreed to buy RAPT Therapeutics for $2.2 billion, accessing the U.S. biotech's experimental drug to treat food allergies as ...
By Pushkala Aripaka Jan 20 (Reuters) - Britain's GSK will buy RAPT Therapeutics for $2.2 billion, adding global rights to the ...
GlaxoSmithKline (GSK) has agreed to acquire Rapt Therapeutics for $2.2 billion, the companies said today, in a deal intended to bolster the buyer’s pipeline with Rapt’s ozureprubart (RPT904), a ...
Zacks.com on MSN
BMY vs GSK: Which Biopharma Giant Has Better Prospects for Now?
Bristol Myers Squibb BMY and GSK PLC GSK are among the largest global biopharma companies with broad and diverse portfolios.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results